K
Kevin Matthew Schlosser
Researcher at Pfizer
Publications - 11
Citations - 465
Kevin Matthew Schlosser is an academic researcher from Pfizer. The author has contributed to research in topics: Indole test & Quinazoline. The author has an hindex of 6, co-authored 11 publications receiving 442 citations.
Papers
More filters
Journal ArticleDOI
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
Gonzales Andrea,Kenneth E. Hook,Irene W. Althaus,Paul A. Ellis,Erin Trachet,Amy M. Delaney,Patricia J. Harvey,Teresa Ellis,Danielle M. Amato,James M. Nelson,David W. Fry,Tong Zhu,Cho-Ming Loi,Stephen Fakhoury,Kevin Matthew Schlosser,Karen Elaine Sexton,R. Thomas Winters,Jessica Elizabeth Reed,Alex J. Bridges,Daniel J. Lettiere,Deborah A. Baker,Jianxin Yang,Helen Lee,Haile Tecle,Patrick W. Vincent +24 more
TL;DR: Oral administration of PF-00299804 causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in ErbB1 (EGFR) associated with resistance to gefitinib and erlotinib.
Journal ArticleDOI
A Highly Efficient Procedure for 3-Sulfenylation of Indole-2-carboxylates
Kevin Matthew Schlosser,Alexei P. Krasutsky,Harriet W. Hamilton,Jessica Elizabeth Reed,Karen Elaine Sexton +4 more
TL;DR: A highly efficient one-pot procedure for 3-sulfenylation of 2-carboxyindoles is described, which is milder, produces less waste, and is compatible with a wide range of thiol and indole functionality.
Journal ArticleDOI
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family
Jeff B. Smaill,Gonzales Andrea,Julie Ann Spicer,Helen Tsenwhei Lee,Jessica Elizabeth Reed,Karen Elaine Sexton,Irene W. Althaus,Tong Zhu,Shannon Leigh Black,Adrian Blaser,William A. Denny,Paul A. Ellis,Stephen Fakhoury,Patricia J. Harvey,Ken Hook,Florence O. McCarthy,Brian D. Palmer,Freddy Rivault,Kevin Matthew Schlosser,Teresa Ellis,Andrew M. Thompson,Erin Trachet,R. Thomas Winters,Haile Tecle,Alexander James Bridges +24 more
TL;DR: Pharmacokinetic comparison of compounds 54 and 71 across three species selected compound 54 as the preferred candidate and has been assigned the nomenclature of dacomitinib and is currently under clinical evaluation.
Patent
4-phenylamino-quinazolin-6-yl-amides
Fakhoury Stephen Alan,Helen Tsenwhei Lee,Jessica Elizabeth Reed,Kevin Matthew Schlosser,Karen Elaine Sexton,Haile Tecle,Winters Roy Thomas +6 more
TL;DR: In this paper, the authors provided quinazoline compounds of the formula: wherein R 1 is halo, R 2 is H or halo; R 3 is a) C 1-C3 alkyl, optionally substituted by halo and R 4 is -(CH2)m-Het; m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof.
Patent
Oral antidiabetic agents
Bigge Christopher Franklin,Alexander James Bridges,Agustin Casimiro-Garcia,Fakhoury Stephen Alan,Helen Lee,Jessica Elizabeth Reed,Schaum Robert Philipp,Kevin Matthew Schlosser,Sexton Karen Elaine,Zhou Hairong +9 more
TL;DR: In this article, the authors provided compounds of Formula (I): f I wherein A, X, Q, Y, B, D, Z, and E have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful as antidiabetic agents.